the struggle for affordable treatment for Spinal Muscular Atrophy (SMA) brought attention to the hurdles faced by individuals with rare diseases. The patient’s legal battle for access to a more reasonably priced version of the drug highlighted the urgency of transparent drug pricing regulations. By advocating for fair pricing practices and promoting competition in the pharmaceutical industry